Laura Lovett
The new funding round brings the company's valuation to $4.6 billion.
Third-party developers can use the platform to build their own products or update instruments.
This IPO comes roughly a year after the company closed a $25 million SPAC.
The company will cater to individuals with serious mental illness and severe depression.
The company plans to put the new funds towards building out its platform.
The effort will be focused on using nocturnal scratch as an endpoint for atopic dermatitis.
The study will focus on Type 2 diabetes patients.
This new infusion of cash brings the company's total funding to $28 million.
The new technology is being developed for in-hospital and at-home use.
Bush discusses his new company Zus and what tech-first providers need right now.